Advaxis, Inc. Receives Orphan Drug Designation For Treatment Of Invasive Cervical Cancer
5/1/2014 9:37:32 AM
PRINCETON, N.J., May 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq:ADXS), a leader in developing cancer immunotherapies, announced today that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer.
Help employers find you! Check out all the jobs and post your resume.
comments powered by